Braile A, Toro G, De Cicco A, Cecere AB, Zanchini F, Schiavone Panni A. Hallux rigidus treated with adipose-derived mesenchymal stem cells: A case report. World J Orthop 2021; 12(1): 51-55 [PMID: 33520681 DOI: 10.5312/wjo.v12.i1.51]
Corresponding Author of This Article
Giuseppe Toro, MD, Surgeon, Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio 4, Naples 80138, Italy. firstname.lastname@example.org
Checklist of Responsibilities for the Scientific Editor of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hallux rigidus treated with adipose-derived mesenchymal stem cells: A case report
Adriano Braile, Giuseppe Toro, Annalisa De Cicco, Antonio Benedetto Cecere, Fabio Zanchini, Alfredo Schiavone Panni
Adriano Braile, Giuseppe Toro, Annalisa De Cicco, Antonio Benedetto Cecere, Fabio Zanchini, Alfredo Schiavone Panni, Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples 80138, Italy
Author contributions: Braile A, Toro G, and Panni AS conceived the study; Cecere AB, and De Cicco AD collected clinical data; Cecere AB, De Cicco AD, and Zanchini F interpreted the obtained data; Braile A and Toro G wrote the article; Panni AS supervised the entire process; all authors revised and approved the final version of the manuscript.
Informed consent statement: As routinely performed, the patient signed a written informed consent in which he authorized the surgical procedure and data collection for research and audit purposes. According to Italian law no formal ethical approval is required for this type of study as it includes routinely performed clinical evaluations.
Conflict-of-interest statement: The authors declare that they had no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Giuseppe Toro, MD, Surgeon, Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Via L. De Crecchio 4, Naples 80138, Italy. email@example.com
Received: July 27, 2020 Peer-review started: July 27, 2020 First decision: September 21, 2020 Revised: October 5, 2020 Accepted: October 20, 2020 Article in press: October 20, 2020 Published online: January 18, 2021
First metatarsophalangeal joint arthritis (FMTPA), also known as hallux rigidus, is the most frequent degenerative disease of the foot. Diagnosis is made through both clinical and radiological evaluation. Regenerative medicine showed promising results in the treatment of early osteoarthritis. The aim of the present study was to report the results of a case of FMTPA treated with the injection of autologous adipose-derived mesenchymal stem cells.
A gentleman of 50 years of age presented with a painful hallux rigidus grade 2 resistant to any previous conservative treatment (including nonsteroidal anti-inflammatory drugs and hyaluronic acid injections). An injection of autologous adipose-derived mesenchymal stem cells into the first metatarsophalangeal joint was performed. No adverse events were reported, and both function and pain scales improved after 9 mo of follow-up.
The FMTP joint injection of mesenchymal stem cells improved symptoms and function in our patient with FMTPA at 9 mo of follow-up.
Core Tip: Recently, the use of intra-articular injections of stem cells has been proposed as a promising treatment in early osteoarthritis. In particular, autologous adipose-derived stem cells (aASCs) have attracted considerable attention, considering the easy access to fat tissue and the absence of adverse events registered. These characteristics make aASCs one of the most promising cell types used in regenerative medicine. Hallux rigidus, is the most frequent degenerative disease of the foot. Patients with hallux rigidus present a history of pain, gait discomfort, articular effusion, and a reduction in range of motion. Different types of treatment are available, both conservative and operative, but both are often ineffective. aASCs might overcome the gap between these two methods of treatment.
Citation: Braile A, Toro G, De Cicco A, Cecere AB, Zanchini F, Schiavone Panni A. Hallux rigidus treated with adipose-derived mesenchymal stem cells: A case report. World J Orthop 2021; 12(1): 51-55
First metatarsophalangeal joint arthritis (FMTPA), also known as hallux rigidus, is the most frequent degenerative arthritis disease of the foot. Depending on the severity of the disease, the symptoms in the case of FMTPA are pain, gait discomfort, articular effusion, and a reduction in range of motion. The diagnosis is generally completed by observing the typical findings of osteoarthritis (OA) revealed by X-rays. Coughlin and Shurnas proposed a classification for FMTPA based on both clinical features and imaging (Table 1).
Table 1 Coughlin and Shurnas clinical and radiographic classification of hallux rigidus.
Mild pain and stiffness pain with maximum dorsiflexion/plantar flexion
Global osteophytes, mild/moderate narrowing
Moderate to severe pain and stiffness relatively constant, pain near extreme ROM
Nearly constant pain and stiffness, no midrange pain
Same as grade 3
Grade 3 + midrange pain
Different types of treatments had been proposed, both conservative [i.e., orthosis, nonsteroidal anti-inflammatory drugs, hyaluronic acid (HA) injections] and operative (i.e., cheilectomy, arthroplasty, arthrodesis).
Recently, emerging evidence has supported the use of autologous adipose-derived mesenchymal stem cells (aAMSCs) for the treatment of early OA[4-7].
The aim of the present study was to report the clinical results of a case of FMTPA treated with the injection of aAMSCs.
A gentleman of 50 years of age presented with a painful FMTP joint in the left foot.
History of present illness
His symptoms were resistant to both nonsteroidal anti-inflammatory drugs and HA injections.
History of past illness
The patient was already scheduled for an aAMSCs injection due to right knee Kellgren-Lawrence grade 2 OA.
Personal and family history
Personal and family history were negative for foot pathologies.
The clinical examination showed a positive axial grind test and joint pain, exacerbated by the dorsiflexion that impaired the patient’s ability to walk.
Laboratory tests did not support the final diagnosis.
Antero-posterior and latero-lateral standard X-rays showed FMTPA stage 2.
FMTPA stage 2 was diagnosed.
The patient was already scheduled for an aAMSCs injection due to right knee Kellgren-Lawrence grade 2 OA, and therefore a similar injection was proposed to treat the hallux rigidus.
Concentrated aAMSCs were obtained from the abdomen, filtered as previously reported, and then injected into the FMTP joint after its distraction (Figure 1).
Figure 1 Intraoperative picture showing the autologous adipose-derived mesenchymal stem cells injection into the first metatarsophalangeal joint.
Protected weight bearing was prescribed during the first week after the procedure.
OUTCOME AND FOLLOW-UP
The patient was followed up at regular intervals. The clinical evaluation was completed using both the American Orthopedic Foot and Ankle Society (AOFAS) for hallux metatarsophalangeal-interphalangeal scale and the Visual Analog Scale (VAS).
No adverse effects were reported, excluding a transient pain in the FMPT joint in the first week after surgery. During the entire follow-up, an improvement in both VAS and AOFAS scales were observed (Table 2), leading to a final VAS scale of 0 and an AOFAS of 78 at 9 mo of follow-up.
Table 2 American Orthopedic Foot and Ankle Society and Visual Analog Scale scores.
AOFAS: American Orthopedic Foot and Ankle Society; VAS: Visual analog scale.
Recently, the use of regenerative medicine principles has been proposed for various applications in both trauma and orthopedics, and especially for the treatment of early OA[4-6,8-11]. While conventional therapies for early OA (i.e. physical therapy, glucosamine and chondroitin sulfate supplementation) showed little benefits, regenerative medicine was demonstrated to be a promising option, due to the paracrine, anti-apoptotic, anti-inflammatory, and anti-aging effects of stem cells[12,13].
aAMSCs showed some theoretical advantages over other sources of stem cells. In fact, aAMSCs are easy to harvest, because of the wide availability of adipose tissue, and their sampling is generally associated with minimal discomfort, considering that it can be carried out using local anesthesia. Moreover, aAMSCs demonstrated a high capacity for proliferation and fibroblastic differentiation. Hass et al showed that adipose tissue should be considered a primary source of cells for regenerative medicine as it contains 500 times more MSCs than the same volume of bone marrow.
Emerging literature has underlined the role of aAMSCs in the treatment of early OA. Schiavone Panni et al conducted a study of 52 patients with early knee OA treated with arthroscopic debridement and aAMSCs injection, and showed improvement in both function and pain at an average of 15.3 mo of follow-up. Similarly, Song et al reported the amelioration of pain, function and cartilage volume of the knee after multiple injections of aAMSCs. The efficacy of aAMSCs in OA was recently confirmed in a systematic review conducted by McIntyre et al.
FMTPA is a degenerative disease with an incidence of 2.5% in patients over 50 years of age. Its treatment might be frustrating for both the orthopedic and the patient, considering the conflicting outcomes reported after conservative treatment, including HA injections. Petrella et al in their study of 47 patients with FTMPA, described the long-term improvement in both pain and function after multiple HA injections; however, Munteanu et al in their randomized controlled trial did not observe any differences when HA was compared with placebo.
Pons et al in a randomized study compared the use of sodium hyaluronate with triamcinolone acetonide in FMTPA, and reported an improvement in pain relief and function at 3 mo after the injections. However, a high percentage of patients in both groups required subsequent surgery after 1 year of follow-up, due to further progression of the disease with worsening of both pain and function.
To the best of our knowledge, this is the first report on the use of aAMSCs for FMTPA. A single injection was effective in treating FMTPA, improving both the AOFAS and VAS score at 9 mo of follow-up.
The present case report indicates that the injection of aAMSCs might be a promising treatment for FMTPA. Obviously, larger cohorts and longer follow-up studies are needed to confirm these findings.